Merck Viresolve® Prefilter for Virus Clearance

Overview

The Merck Viresolve® Prefilter is an engineered prefiltration solution designed specifically to safeguard and enhance the performance of the Viresolve® Pro virus removal filter in biopharmaceutical downstream processing. Operating on the principle of depth filtration combined with surface retention, the prefilter removes particulate matter, aggregated proteins, lipids, and other process-related impurities that would otherwise prematurely foul or reduce the capacity of the downstream virus clearance membrane. This staged filtration architecture ensures robust, reproducible viral clearance across varying feedstock conditions—critical for maintaining regulatory compliance and process consistency during clinical and commercial manufacturing of monoclonal antibodies, recombinant proteins, vaccines, and gene therapy vectors.

Key Features

• Engineered compatibility with Viresolve® Pro filters to maximize throughput and extend service life under high-flux operating conditions
• Scalable design supporting linear scale-up from lab-scale OptiScale®-40 capsules (5 cm² effective filtration area) to production-scale Pod configurations (up to 1.1 m² per unit)
• Depth-filtration media optimized for high particle loading capacity while preserving low protein binding and minimal leachables profile
• Single-use, gamma-irradiated construction compliant with ISO 11663:2021 for integrity-tested sterile filtration devices
• Luer-lock inlet/outlet connections on OptiScale®-40 units enabling rapid, leak-free setup in small-volume process development workflows
• Modular stainless-steel clamping systems for Pod assemblies—designed for non-product-wetted contact and compatible with existing tangential flow or dead-end filtration skids

Sample Compatibility & Compliance

The Viresolve® Prefilter demonstrates broad compatibility with clarified mammalian cell culture harvests (e.g., CHO, HEK293), microbial lysates, and purified intermediate streams across pH 4.5–8.5 and conductivity ranges up to 20 mS/cm. It has been validated in conjunction with Viresolve® Pro for removal of model viruses including MMV, PRV, and X-MuLV, meeting ICH Q5A(R2) requirements for viral clearance validation. Manufacturing adheres to ISO 9001:2015 quality management standards and follows cGMP principles aligned with FDA 21 CFR Part 211 and EU Annex 1. Filter integrity testing protocols support both water intrusion (for hydrophobic variants) and forward flow methods per ASTM F838-22.

Software & Data Management

While the Viresolve® Prefilter itself is a passive, single-use hardware component, its integration into automated bioprocessing platforms—including those equipped with DeltaV™, DCS, or PAT-enabled control systems—enables full traceability via electronic batch records (EBRs). When used with Merck’s Process Validation Toolkit and Filter Integrity Test Log software, users can generate audit-ready documentation satisfying FDA 21 CFR Part 11 requirements, including user authentication, electronic signatures, and immutable data archiving. All filter lot-specific certificates of conformance, test reports, and extractables profiles are accessible through Merck’s online Quality Documentation Portal.

Applications

• Process development and optimization of virus clearance steps in early-phase biologics manufacturing
• Robustification of viral filtration processes subject to feedstream variability (e.g., batch-to-batch differences in turbidity, host cell protein content, or freeze-thaw effects)
• Cost-effective mitigation of filter fouling in high-titer mAb purification trains
• Linear scale-up from benchtop (OptiScale®-40) to pilot (Pod with mid-scale clamp) and commercial (multi-Pod rack systems) operations
• Supporting platform process strategies where standardized prefiltration reduces qualification burden across multiple product families

FAQ

Can the Viresolve® Prefilter be used with filters other than Viresolve® Pro?

Yes—while optimized for use with Viresolve® Pro, the prefilter may be evaluated with other virus-retentive membranes; however, compatibility testing for flux, capacity, and viral log reduction value (LRV) must be performed per ICH Q5A(R2) guidelines.
Is the OptiScale®-40 capsule suitable for regulatory submission studies?

Yes—OptiScale®-40 units are manufactured under the same quality system as production-scale filters and include full traceability, certificate of conformance, and extractables data required for inclusion in regulatory filings.
What integrity test method is recommended for Pod-style prefilter assemblies?

Forward flow testing is recommended for all Pod configurations; test parameters (e.g., hold time, pressure, temperature) must be qualified per filter lot and system configuration.
Are there documented case studies demonstrating cost savings using this prefilter?

Multiple peer-reviewed publications and Merck technical bulletins report up to 2.3× increase in Viresolve® Pro throughput and ≥40% reduction in total cost of viral clearance per kg of product, attributable to extended filter lifetime and reduced buffer consumption.